PRTA Logo

Prothena Corporation plc (PRTA) 

NASDAQ
Market Cap
$976.11M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
681 of 776
Rank in Industry
367 of 433

Largest Insider Buys in Sector

PRTA Stock Price History Chart

PRTA Stock Performance

About Prothena Corporation plc

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and …

Insider Activity of Prothena Corporation plc

Over the last 12 months, insiders at Prothena Corporation plc have bought $0 and sold $525,952 worth of Prothena Corporation plc stock.

On average, over the past 5 years, insiders at Prothena Corporation plc have bought $54.55M and sold $25.48M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 1,062,736 shares for transaction amount of $30.84M was made by EcoR1 Capital, LLC () on 2022‑05‑05.

List of Insider Buy and Sell Transactions, Prothena Corporation plc

2024-01-24SaleChief Accounting Officer
5,000
0.0096%
$34.00$170,000-33.91%
2023-12-20SaleChief Accounting Officer
5,000
0.0094%
$37.19$185,952-40.05%
2023-11-30SaleChief Accounting Officer
5,000
0.0097%
$34.00$170,000-29.38%
2023-10-25SaleChief Accounting Officer
5,000
0.0097%
$41.04$205,191-39.39%
2023-10-11SaleChief Operating Officer
4,000
0.0074%
$46.75$186,985-46.85%
2023-10-04SaleChief Regulatory Officer
5,000
0.0093%
$46.62$233,084-43.55%
2023-09-27SaleChief Legal Officer
5,000
0.0093%
$47.38$236,885-44.72%
2023-09-19SaleChief Accounting Officer
5,000
0.0093%
$52.36$261,807-48.68%
2023-09-13SaleChief Operating Officer
4,000
0.0075%
$55.49$221,963-49.31%
2023-09-13SaleChief Medical Officer
2,000
0.0037%
$55.48$110,952-49.31%
2023-09-06SaleChief Regulatory Officer
5,000
0.0093%
$54.76$273,804-49.33%
2023-08-30SaleChief Legal Officer
5,000
0.0095%
$55.01$275,066-47.85%
2023-08-18SaleChief Accounting Officer
5,000
0.0096%
$57.18$285,923-48.19%
2023-08-16SaleChief Operating Officer
4,000
0.0075%
$58.71$234,844-49.60%
2023-08-16SaleChief Medical Officer
2,000
0.0038%
$58.74$117,480-49.60%
2023-08-02SaleChief Scientific Officer
4,000
0.0075%
$67.05$268,182-51.93%
2023-08-02SaleChief Regulatory Officer
5,000
0.0094%
$67.01$335,072-51.93%
2023-07-26SaleChief Legal Officer
5,000
0.0095%
$62.33$311,638-47.96%
2023-07-19SaleChief Accounting Officer
5,000
0.0099%
$69.19$345,943-50.39%
2023-07-12SaleChief Operating Officer
4,000
0.0076%
$67.51$270,026-50.52%

Insider Historical Profitability

56.69%
EcoR1 Capital, LLC
11584280
21.54%
$18.1591+87.11%
Kinney Gene G.President and CEO
12793
0.0238%
$18.15113+13.42%
Schenk Dale B.President and CEO
3333
0.0062%
$18.1512+5.51%
Nguyen TranChief Strategy Officer and CFO
3200
0.006%
$18.15210+10.25%
Nickerson TaraChief Business Officer
2000
0.0037%
$18.1517+5.51%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Ecor1 Capital Llc$286.94M21.5411.58M0%+$02.01
Fidelity Investments$198.32M14.898.01M-0.54%-$1.07M0.01
T. Rowe Price$104.08M7.814.2M-0.84%-$881,326.190.01
Wellington Management Company$92.94M6.983.75M+44.64%+$28.68M0.02
BlackRock$92.11M6.923.72M-1.38%-$1.28M<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.